KR20120111125A - Composition for treatment of renal cell carcinoma and functional food comprising extract of cannabis semen - Google Patents

Abstract

PURPOSE: A composition and a functional food containing Cannabis Semen ethanol extract are provided to effectively prevent and treat renal cancer. CONSTITUTION: A composition for preventing and treating renal cancer contains Cannabis Semen ethanol extract as an active ingredient, which is prepared by extracting at 50 Deg. C. for 24 hours. The composition also contains pharmaceutically acceptable carriers or dilents. A functional food for preventing renal cancer contains the extract as an active ingredient, containing sitologically acceptable food additives. [Reference numerals] (AA) Relative cell survival rate

Description

Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Cannabis Semen}

The present invention relates to a novel use of madin extract. Specifically, the present invention relates to a therapeutic composition and functional food containing as soon as the active ingredient extract showing excellent prophylactic or therapeutic efficacy against kidney cancer.

Among the major diseases of modern people, researches on the treatment and diagnosis of cancer are being conducted mainly on lung cancer, liver cancer, and stomach cancer, which have high incidence.

The kidney is an important urinary system that has the role of excreting waste products in vitro by filtering blood to produce urine. At the same time, it is also an important endocrine organ that produces hormones such as angiotensin, which regulates blood pressure, and erythropoietin, a red blood cell hematopoietic factor. Renal tumors include kidney cell cancer in adults, Wilms' tumor in children, and sarcoma as a rare tumor, but the most common malignancy below Renal cell cancer, a tumor, is called kidney cancer. The incidence of renal cancer is about 2.5 per 100,000 population, and male to female ratio is 2 to 3: 1. Among urological malignancies, there are many tumors following prostate cancer and bladder cancer.

Genetic factors are also known as risk factors for kidney cancer, but generally include smoking and excessive fat intake. It is also known that the incidence of such tumors is high in patients undergoing long-term dialysis. In kidney cancer, when the tumor has a maximum diameter of 5 cm or less, some subjective symptoms rarely occur and are often found by CT scan or the like at the time of examination. Larger tumors may include hematuria, abdominal tumors, and pain. In addition, systemic symptoms may cause fever, weight loss, anemia and the like, and rarely, endocrine factors may cause erythrocytosis, hypertension, hypercalcemia, and the like. On the other hand, there may be cases in which vein veins of the abdominal body surface or venous varicose veins occur due to the progression of kidney cancer into the inferior vena cava. About 20% of kidney cancers are found from lung or bone metastases. In kidney cancer, tumors tend to spread in veins, and metastasis to other organs is likely to occur.

Ultrasound, CT, angiography, etc. are examined for kidney cancer, but specific biochemical markers are not known. Therefore, examination using a device is necessary. In addition, although several types of kidney cancer can be classified pathologically, the cause of the development of clear cell type kidney cancer, which accounts for about 90%, is known to be a defect in the von-Hippel-Lindau (VHL) gene, a cancer suppressor gene. . Deletion of the VHL gene results in transcriptional activation of the hypoxic inducible gene group through association of HIF-α / VHF, leading to enhanced expression of genes such as VEGF and TGFβ.

The main treatment for kidney cancer is surgical therapy. Regardless of the timing of the disease, extraction of the kidneys or partial extraction of the kidneys is the most common where possible, and even if there is metastasis, surgical removal of the kidneys may be considered. Arterial embolization of the renal artery may be used as a method other than the surgical therapy. This method may be performed prior to surgery in cases where it is impossible to extract or when a large tumor is removed. Recent advances in burn diagnostics have led to early detection of renal cancer, even at very small sizes, resulting in more than 90% healing in early cancer. However, since the therapeutic results of large tumors larger than 5 cm or tumors with metastases are poor (the 5-year survival rate of all renal cell carcinomas is about 50 to 60%), the importance of early detection is recognized.

On the other hand, Cannabis Semen is a dried seed of Cannabis sativa L. of the genus Moraceae, whose origin is the annual herb of Central Asia, whose main stem is 1-2.5 m high and grows straight. With fine hairs and green. The leaves are vivid at the bottom, long lobes, long intestinal bile divided into 5-9, but the upper part is shorted without splitting or splitting into three. Tetrahydrocannabinol, known as hemp, has psychotropic effects and initially produces pleasure and hallucination with the central nervous system and cerebral spinal cord, which pass into paralysis. At the same time, the dense horse comes to the sensory spirits, bringing about the loss of pain, and eventually reaches the communist zone. As soon as it is intestine moisturizes, and combined with passersby, peony, fruit room, rhubarb, bakbak is used to treat constipation. In other words, as soon as the chapter through the stools to come out well. It can be applied to constipation (Park Jong-hee, co-author Lee Jeong-gyu, commercial medicinal plant illustration, p199-p201). As soon as it is dry, it helps to smoothly communicate the intestines and improves blood circulation.

In other words, Cannabis Semen ( Cannabis Semen ) is a seed of hemp ( cannabis sativa L.) (Moraceae family) used for the purpose of yunjangcheong, hemophilia, intestinal constipation, gastrointestinal tightening, medicinal constipation in oriental medicine and private.

Korean Unexamined Patent Publication No. 2003-0059951 includes a herbal compound containing mazain, that is, an extract consisting of rhubarb, chason, ulriin, betel nut, mazain, earth and sand, dew, pesticide, cornus, fruiting, windproof and poisonous A composition for preventing and treating diabetes is disclosed, and Korean Laid-Open Patent Publication No. 1999-0084271 discloses a tea having a constipation symptom improvement effect including mazain and a method for manufacturing the same, and the Republic of Korea Patent Publication No. 10- 0630410 discloses a topical composition for the prevention and treatment of acne containing the extract of Mazarin. The present invention relates to a composition containing the herbal extract having the ability to inhibit the growth of the ear, synagogues, maine, white oysters and corydalis showing a proliferation inhibitory effect of P. acnes at low concentrations. However, nothing has been disclosed or disclosed in this document in connection with kidney cancer-related diseases of mazain.

Thus, the present inventors completed the present invention by confirming that the extract of the mother can effectively kill kidney cancer cells during the study of herbal medicine for the mother.

It is an object of the present invention to provide a composition for treating kidney cancer and a functional food containing the extract as an active ingredient.

In order to achieve the above object, the present invention provides a composition for preventing and treating kidney cancer containing Cannabis Semen ethanol extract as an active ingredient.

In addition, the present invention provides a functional food for preventing kidney cancer containing Cannabis Semen ethanol extract containing a food supplement acceptable food supplement as an active ingredient.

 Hereinafter, the present invention will be described in detail.

The present invention provides a composition for the prevention and treatment of kidney cancer containing Cannabis Semen ethanol extract as an active ingredient. The composition of the present invention comprises a extract as soon as the active ingredient, and may further comprise a pharmaceutically acceptable carrier or diluent.

In the composition for preventing and treating kidney cancer of the present invention, the ethanol extract is preferably extracted at 50 ° C. for 24 hours, wherein the ethanol extract is more preferably dried and concentrated at 45 ° C. under reduced pressure, and the ethanol Is most preferably 95%.

In addition, in the composition for preventing and treating kidney cancer of the present invention, the kidney cancer is preferably renal cell cancer.

As soon as the extract of the present invention is possible at any site of the mother, it is preferably extracted from the root. The extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane. Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.

Specifically, 1 to 5 times, preferably 3 times, 95% ethanol is added to the dried or powder as soon as 10 to 100 hours, preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C. After extracting for 40 hours, more preferably 24 hours, the ethanol extract may be prepared by filtering. Preferably, the filtrate obtained by filtering the extract may be concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.

The "pharmaceutically acceptable carrier" is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.

The composition for treating kidney cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .

Formulations for the formulation of the extract of the present invention can be administered orally at the time of clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and liquid preparations for oral use include suspensions, solvents, emulsions, and syrups. In addition to liquids and paraffins, various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.

In addition, the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng (Gingseng), Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Windproof (Ledebouri) ), Ginger (Zingiberis Rhizoma crudus), forget-me-not (Natrii sulfas), control (Ziz) yphi Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Mint Herba, Dioscoreae Rhizoma, Polyporus, Polygoni multiflori Radix, Gusi (Allii tube) Semen, Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Anemarrhen Rhizoma, Carthami Flos, Astragali Radix, Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, Cortexi radics ), Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Malt (Hordei Fructus germinatus), Cuscutae Semen, Mordaedae Radix, Sea Song (Pini koraiensis) Radix) and the like can be used alone or in combination.

The composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like. In addition to water, liquid, and paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Specifically, preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. In addition, calcium or vitamin D ₃ may be added to enhance the efficacy of the treatment. Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

The formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination. The invention also includes formulations of dosage units. The formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage. Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times. The individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.

As used herein, the term "extract" refers to an active ingredient isolated from natural products. The extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.

In a specific embodiment of the present invention, the ethanol extract of mazain killed 89.9% of ACHN kidney cancer cells at 100 μg / ml and the EC ₅₀ (half maximal effective concentration) was 39.7 μg / ml. The above results demonstrate that the extract of the present invention has excellent killing activity of ACHN renal cancer cells, and further has renal cancer treatment and prophylactic activity.

As used herein, the term "prevention" means any action that inhibits or delays the development of kidney cancer by administration of the composition.

As used herein, the term "treatment" means any action that improves or advantageously changes the symptoms of kidney cancer by administration of the composition.

As soon as the extract in the present invention can be extracted using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol. The extracted solution can be used directly or can be concentrated and / or dried. When extracted with an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like. Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.

Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration. The drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.

In addition, the extract can perform an additional fractionation process. Preferably, the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.

In the present invention, the term "pharmaceutically acceptable salts" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , Benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.

The pharmaceutical composition for preventing and treating kidney cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like. In addition, the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as. In addition, the composition may include a substance having a therapeutic activity against kidney cancer used alone or used in the past.

As used herein, the term "patient" refers to humans, horses, sheep, pigs, goats, and camels having a disease caused by kidney cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means animals such as nutrition, dogs. By administering to a patient a composition comprising the extract of as soon as the present invention, it is possible to effectively prevent and treat the above-mentioned kidney cancer. The composition of the present invention can be administered in parallel with existing kidney cancer treatments.

As used herein, the term "administration" means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered. In addition, the composition may be administered by any device in which the active agent may migrate to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration. In general, when the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day. Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.

In another aspect, the present invention provides a functional food for preventing kidney cancer containing Cannabis Semen ethanol extract containing a food supplement acceptable food additive as an active ingredient.

Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight. Functional food of the present invention is not particularly limited in the formulation, for example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, Various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.

In the present invention, "functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functional" refers to the structure of the human body And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.

In the present invention, as a result of injecting the extract of the present invention into ACHN kidney cancer cells, it was confirmed that the ACHN kidney cancer cells die (see Fig. 1 ). Therefore, it can be seen that the extract as soon as there is a therapeutic effect for kidney cancer. Thus, in the present invention, the present invention was completed by preparing a functional food for preventing kidney cancer containing the extract as soon as the active ingredient (see Preparation Example 2 ).

As described above, as soon as the extract of the present invention inhibits the growth of kidney cancer cells and induces apoptosis. Therefore, the composition for treating renal cancer according to the present invention will be very effective in the treatment of renal cancer patients.

1 is a result of the Alamar Blue analysis to determine the effect of the introduction of Mazarin in human kidney cancer ACHN cells on the growth of kidney cancer cells. In the figure, the horizontal axis shows the concentration of the extract, and the vertical axis shows the survival rate of kidney cancer cells.

Hereinafter, the present invention will be described in more detail based on the following examples. It should be noted, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The present invention is not limited to the following examples. Will be apparent to those skilled in the art to which the present invention pertains.

Example 1 Preparation of Mazarine Extracts

3 kg of mazain (made in China) purchased from Seoul medicinal herb was dried and ground at room temperature for 5 days. The ground mazain was soaked in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 418 g of the total extract, which was stored at −20 ° C.

Example 2 Effect of Mazain Extract on the Growth of Kidney Cancer Cells

In order to determine the effect of the extract extracted from Example 1 on the growth of renal cancer cells, ACHN cells, which are human renal cancer cells, were treated with ethanol extracts of madin for 48 hours and subjected to Alamar Blue analysis. The Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.

<2-1> Preparation and Treatment of Human Kidney Cancer Cell Line

ACHN cells, a kidney cancer cell line used in the present invention, were distributed from Korean Cell Line Bank (KCLB) and used for experiments. Specifically, ACHN kidney cancer cells (Minimum essential medium) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subcultured in medium.

<2-2> Cell growth inhibition measurement of ACHN kidney cancer cells

As soon as the extract extracted in Example 1 was confirmed the effect of inhibiting growth against ACHN cells which are kidney cancer cells. Specifically, after injection of 6.0 × 10 ³ ACHN kidney cancer cells per well into a 96 well plate and incubating for 24 hours, the mother dissolve in DMSO (dimethyl sulfoxide) When the ethanol extract was treated at concentrations of 0 to 100 μg / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50, and 100 μg / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1 and FIG. 1). After treatment with each concentration of extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of cell culture filled in each well in a 96-well plate, and the plates were incubated for 2 hours in an incubator. The plate was slowly shaken to evenly react the cells in each well, and the intensity of fluorescence was measured at 590 nm with a Fluorescence Microplate Reader (Molecular Devices Corp.) while irradiating irradiated light at a wavelength of 544 nm. The survival rate of is shown in FIG.

Mazarine Concentration Kidney Cancer Cell Survival (Average) Standard Deviation 0 μg / ml 1,000 0.000 3.125 μg / ml 0.980 0.021 6.25 μg / ml 0.967 0.016 12.5 μg / ml 0.917 0.014 25 μg / ml 0.738 0.021 50 [mu] g / ml 0.383 0.006 100 μg / ml 0.101 0.003

As a result, as shown in Table 1 and Figure 1, as the concentration of the treatment of the higher the growth of kidney cancer cells was reduced, it can be seen that as soon as having the effect of renal cancer treatment. Ie 2.0% at 3.125 μg / ml, 3.3% at 6.25 μg / ml, 8.3% at 12.5 μg / ml, 26.2% at 25 μg / ml, 61.7% at 50 μg / ml, 89.9% at 100 μg / ml Kidney cancer cells were killed. In addition, an EC ₅₀ (half maximal effective concentration) was determined to be 39.7 μg / ml. In Table 1, the relative cell numbers of kidney cancer cells after 48 hours according to the concentrations of the respective treatments based on the number of survival rates of the kidney cancer cells of the control group not treated with mazain were described as 1. As such, the extract of the present invention has excellent ACHN cell killing activity and further demonstrates that it has therapeutic and prophylactic activity for kidney cancer.

Example 3 Acute Toxicity Test with Mazarin Extracts

As soon as it was determined that there is no problem in stability as it is widely used as a medicinal herb, the purpose of this study was to confirm the toxicity by oral administration and intraperitoneal administration.

Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg, each of the extract of Example 1 of the present invention suspended in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemistry test, autopsy findings, etc. As a result, all of the extracts did not show toxic changes up to 5 g / kg in rats, and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of 5 g / kg or more.

Preparation Example 1 Preparation of a Renal Cancer Therapeutic Agent Containing Mazarin Extract as an Active Ingredient

The present inventors have confirmed that the kidney cancer treatment effect of the extract as soon as through the above example was prepared for the treatment of kidney cancer containing the extract as an active ingredient as soon as. In addition, the preparation of the following therapeutic agent can be used for the application of not only a therapeutic agent but also a health food.

<1-1> Soft gelatin capsules containing Mazarin extract

Mazarin Extract 20%

Vitamin C 4.5%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

10% wax

Palm oil 25%

Safflower Seed Oil 30.399%

 <1-2> Mazain  Preparation of Intravenous Formulation Containing Extract

Mazarin Extract 0.2%

Mannitol 0.3%

Saline 9.5%

<1-3> Tablet containing Mazarin extract

Mazarin Extract 35%

Vitamin C 10%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

Crystalline cellulose 25.0%

Lactose 17.999%

Magnesium Stearate 2%

Preparation Example 2 Preparation of Functional Foods Containing Mazain Extract as Active Ingredient

The present inventors confirmed that as soon as the extract extract as soon as the kidney cancer therapeutic activity through the above-mentioned to prepare a functional food containing it as an active ingredient as follows.

<2-1> Preparation of Drink

522 mg of honey

Chioctosanamide 5 mg

Nicotinamide 10 mg

Riboflavin Sodium Hydrochloride 3 mg

Pyridoxine hydrochloride 2 mg

Inositol 30 mg

Orthoic acid 50 mg

Mazarin Extract 0.48 ~ 1.28 mg

200 ml of water

A beverage was prepared using the above-mentioned composition and content by a conventional method.

<2-2> production of chewing gum

Gum base 20%

Sugar 76.36-76.76%

Mazarin Extract 0.24 ~ 0.64%

1% fruit flavor

Water 2%

Chewing gum was prepared using the above-mentioned composition and content by a conventional method.

<2-3> Preparation of Candy

Sugar 50-60%

Starch syrup 39.26 ~ 49.66%

Mazarin Extract 0.24 ~ 0.64%

Orange flavor 0.1%

The composition and the content of the candy were prepared using a conventional method.

<2-4> Preparation of Biscuits

Force Class 1 88 kg

Gravity First Class 76.4 ㎏

16.5 kg

2.5 kg of salt

2.7 kg of glucose

Palm shortening 40.5 kg

5.3 kg of ammo

Medium kg 0.6 kg

0.55 kg sodium bisulfite

Rice flour 5.0 kg

Vitamin B1 0.003 kg

0.003 kg of vitamin B2

Milk Flavor 0.16 ㎏

71.1 kg of water

Whole milk powder 4 kg

Substitute powder 1 kg

0.1 kg of calcium phosphate

Spray salt 1 kg

25 kg of spray oil

Mazarin Extract 0.2 ~ 0.5 kg

Biscuits were prepared using conventional methods with the above composition and content.

<2-5> Preparation of Ice Cream

Milkfat 10.0%

Non-fat solids 10.8%

Sugar 12.0%

Starch syrup 3.0%

Emulsifying stabilizer (span) 0.5%

Spices (Strawberries) 0.15%

Water 63.31 ~ 62.91%

Mazarin Extract 0.24 ~ 0.64%

Ice cream was prepared using conventional methods using the above composition and content.

<2-6> manufacturing of chocolate

Sugar 34.36-34.76%

Cocoa Butter 34%

Cocoa Mass 15%

Cocoa Powder 15%

Lecithin 0.5%

0.5% vanilla

Mazarin Extract 0.24 ~ 0.64%

With the above composition and content, chocolate was prepared using conventional methods.

On the other hand, the specific scope of the present invention is defined by the claims rather than the embodiments described above, all changes and modifications derived from the meaning and scope and equivalent concepts of the claims to the scope of the invention It should be interpreted as including.

Claims (7)

Cannabis Semen ( Cannabis Semen ) A composition for preventing and treating kidney cancer, which contains ethanol extract as an active ingredient.
According to claim 1, wherein the ethanol extract is a composition for preventing and treating kidney cancer, characterized in that extracted for 24 hours at 50 ℃.
The composition for preventing and treating kidney cancer according to claim 1 or 2, wherein the ethanol extract is dried and concentrated at 45 ° C under reduced pressure.
According to claim 1 or claim 2, wherein the ethanol is a composition for the prevention and treatment of kidney cancer, characterized in that 95%.
The method of claim 1, wherein the composition is a composition for preventing and treating kidney cancer, characterized in that it comprises a pharmaceutically acceptable carrier or diluent.
The composition for preventing and treating kidney cancer according to claim 1, wherein the kidney cancer is renal cell cancer.
Functional food for the prevention of kidney cancer containing Cannabis Semen ethanol extract containing a food supplement acceptable food supplement as an active ingredient.

Images